Acadia Pharma (ACAD) Reports In-Line Q4 EPS
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $23.39 +3.50%
EPS Growth %: -62.5%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: -62.5%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.65), in-line with the analyst estimate of ($0.65). Revenue for the quarter came in at $11.96 million versus the consensus estimate of $9.05 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Odysight.AI Inc. (ODYS) PT Lowered to $6 at Benchmark
- Hertz cuts guidance, announces notes and stock offerings, shares sink
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
